Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravenous ferric carboxymaltose versus oral iron in HFpEF with iron deficiency anemia
2016-003604-31Phase 4Active
- Sponsor
- IRBLleida
- Start
- Nov 2016
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of ferric carboxymaltose, ferroglycine sulfate, ferric pyrophosphate in heart failure with preserved ejection fraction (HFpEF), iron deficiency anemia (IDA), sponsored by IRBLleida. Started Nov 2016; status: active.
02
Drugs
ferric carboxymaltoseferroglycine sulfateferric pyrophosphate
03
Conditions
heart failure with preserved ejection fraction (HFpEF)iron deficiency anemia (IDA)
Beyond the preview
Go deeper on 2016-003604-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003604-31.